SOURCE: Conversant Bio

Conversant Bio

January 12, 2016 04:00 ET

Conversant Bio Introduces Two New Products for Molecular Diagnostic and Circulating Tumor DNA Researchers

Global Leader in Providing High-Quality Cell Samples Now Offering Annotated FFPE for Common Mutations, and Matched FFPE and Plasma Sets

HUNTSVILLE, AL--(Marketwired - January 12, 2016) -  Conversant Bio, a global leader in supplying the highest-quality human tissue and viable cell samples, today introduced two products that will offer researchers faster access to the cell samples that drive their molecular diagnostic and circulating tumor DNA projects: FFPE annotated for the most common clinically relevant mutations, and matched FFPE and plasma sets.

With the mutation FFPE samples, Conversant Bio helps researchers by completing the screening process for them. This allows research teams to save significant time and resources and begin their projects as soon as they receive their FFPE. The point mutations Conversant Bio have identified include:

  • Colorectal Cancer: KRAS, BRAF, NRAS, PIK3CA
  • Lung Cancer: EGFR, KRAS
  • Breast Cancer: PIK3CA
  • Melanoma: BRAF, NRAS

These mutations have been confirmed by PCR using a proprietary lab-developed test in Conversant Bio's partner CLIA lab.

In addition to characterized FFPE, Conversant Bio is also collecting matched FFPE and plasma sets for Colorectal Cancer, Breast Cancer, and Kidney Cancer. Blood-based biopsies are a way to diagnose and monitor disease progress through circulating cell-free tumor DNA or other biomarkers in the blood. In order to optimize these techniques, researchers need access to both tissue and blood from cancer patients. The matched FFPE and plasma sets that Conversant Bio provides come with patient data including demographic information, a pathology report, current treatments, and block QC information, and are collected under strict SOPs with circulating tumor DNA and other biomarker comparisons in mind.

"We know that researchers should have quick access to samples," says Marshall Schreeder, chief executive officer for Conversant Bio. "We believe this is critical in changing healthcare and bringing about better patient care. These new products will aid important projects that, hopefully, will result in research breakthroughs in molecular diagnostics and circulating tumor DNA studies."

A partial list of Conversant Bio's FFPE inventory can be accessed at http://www.conversantbio.com/ffpe-inventory. To learn more about the company's other services, visit http://www.conversantbio.com.

About Conversant Bio
Conversant Bio provides researchers around the world with hyper-annotated tissue samples in order to conduct informed, cutting-edge investigations into many of today's most problematic diseases. With a large prospective collections network of more than 60 U.S.-based clinical sites and an IRB-reviewed chain of custody quality control system, Conversant Bio provides the highest-quality samples on time and on budget. For additional information about Conversant Bio's services, visit the company's website at http://www.conversantbio.com.

Contact Information